- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03808844
A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion for the Induction of General Anesthesia in Elective Surgery Subjects
A Multi-Center, Randomized, Double-Blind, Propofol-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion for the Induction of General Anesthesia in Elective Surgery Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Chengdu, China
- West China Hospital of Sichuan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- In-patients requiring tracheal intubation under general anesthesia for non-emergency, non-cardiothoracic, and non-extracerebral elective surgeries;
- Male or female, ages between 18-64 (inclusive);
- ASA (American Society of Anesthesiologists) Class I-II (see Appendix 4);
- Body mass index (BMI) ≥18 and ≤30 kg/m2;
- Vital signs: Respiratory rate ≥10 and ≤24 breaths per minute; blood oxygen saturation (SpO2) when inhaling ≥95%; systolic blood pressure (SBP) ≥90 mmHg and ≤160 mmHg; diastolic blood pressure (DBP) ≥60 mmHg and ≤100 mmHg; heart rate ≥55 and ≤100 bpm;
- Subjects must understand the procedures and methods of this study, and be willing to provide informed consent and to complete the trial in strict accordance with study protocol.
Exclusion Criteria:
- Patients with contraindications to general anesthesia or previous history of anesthesia accidents;
- Known hypersensitivity to excipients and ingredients found in propofol and HSK3486 injections (soybean oil, glycerin, triglycerides, egg lecithin, sodium oleate, and sodium hydroxide), benzodiazepines, opioids, rocuronium bromide, sevoflurane, atropine, and neostigmine; cross-reactivity to halogenated anesthetics, jaundice or unexplained fever from previous use of halogenated anesthetics; contraindications to propofol;
Medical history or evidence of any of the following prior to screening/at baseline, which may increase sedation/anesthesia risk:
- History of cardiovascular diseases: Uncontrolled hypertension or SBP >160 mmHg and/or DBP >100 mmHg despite antihypertensive treatment, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medication, third-degree atrioventricular block or QTcF interval ≥450 ms (Fridericia's correction formula, see Appendix 2) during screening;
- Respiratory system disorders: Respiratory insufficiency, history of obstructive pulmonary disease, history of bronchospasm requiring treatment within 3 months prior to screening, acute respiratory tract infection with obvious symptoms such as fever, wheezing, or productive cough within 1 week prior to baseline;
- History of cerebrovascular disease: History of craniocerebral injury, convulsions, epilepsy, intracranial hypertension, cerebral aneurysm, or cerebrovascular accident; history of schizophrenia, mania, chronic use of antipsychotics, or cognitive impairment;
- Gastrointestinal disease history: Gastrointestinal retention, active hemorrhage, or circumstances that may lead to reflux and aspiration;
- Patient with a history of uncontrolled and clinically significant liver, kidney, blood system, nervous system or metabolic system diseases judged by the investigator to be unsuitable for this trial;
- History of alcohol abuse within 3 months prior to screening, abuse defined as average of >2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine);
- History of drug abuse within 3 months prior to screening;
- Serious infection, trauma, or major surgery within 4 weeks prior to screening;
Any one of the following respiratory risks before/during screening:
- Asthma history, and stridor;
- Sleep apnea syndrome;
- History of malignant hyperthermia or family history;
- History of failed tracheal intubation;
- Judged by the investigator to have difficult airway or judged as difficult tracheal intubation (modified Mallampati score III or IV );
In receipt of any of the following drugs or therapies prior to screening:
- Participated in other drug trials within 1 month prior to screening;
- In receipt of medications that may affect QT interval within 2 weeks prior to screening (see Appendix 5);
- In receipt of medications that induce or inhibit cytochrome P450 isoenzyme CYP2B6 within 2 weeks prior to screening (see Appendix 6);
- In receipt of propofol, other sedatives/anesthetics, and/or opioid analgesics or compounds containing analgesics within 3 days prior to screening.
Laboratory results meeting any of the following criteria during screening/at baseline, confirmed by re-examination:
- Neutrophil count ≤1.5×109/L;
- Platelet count <80×109/L;
- Hemoglobin <90 g/L (no blood transfusion within the last 14 days);
- ALT and/or AST ≥2.0×upper limit of normal (ULN);
- Total bilirubin ≥2.0×ULN;
- Serum creatinine ≥1.5×ULN.
- Women who are pregnant or breastfeeding; women of child-bearing potential or men who are unwilling to use contraception during the trial; subjects who are planning pregnancy within 1 month after the completion of the trial (including male subjects);
- Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HSK3486
0.4mg/kg/0.2 mg/kg
|
Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
|
Active Comparator: Propofol
2.0mg/kg/1.0mg/kg
|
Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The success rate of induction of anesthesia
Time Frame: During induction of general anesthesia on day 1
|
During induction of general anesthesia on day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse events
Time Frame: Pre-dose to 48 hours post-dose
|
Safety endpoints
|
Pre-dose to 48 hours post-dose
|
Time to successful anesthetic induction
Time Frame: From the initial administration of the investigational drug to the first time when MOAA/S is ≤1 on day 1
|
From the initial administration of the investigational drug to the first time when MOAA/S is ≤1 on day 1
|
|
Time to loss of eyelash reflex
Time Frame: From the initial administration of the investigational drug to loss of eyelash reflex on day 1
|
From the initial administration of the investigational drug to loss of eyelash reflex on day 1
|
|
Use of the investigational drug and alternative drugs
Time Frame: During induction of general anesthesia on day 1
|
During induction of general anesthesia on day 1
|
|
Use of the alternative drugs
Time Frame: During induction of general anesthesia on day 1
|
During induction of general anesthesia on day 1
|
|
Changes in bispectral index (BIS)(score:0~100)
Time Frame: During induction of general anesthesia on day 1
|
During induction of general anesthesia on day 1
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSK3486-302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Induction of Anesthesia
-
Sichuan Provincial People's HospitalNot yet recruitingInduction of Anesthesia
-
University of UtahNot yet recruiting
-
Cairo UniversityRecruiting
-
Ajou University School of MedicineNot yet recruitingInduction of General Anesthesia
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompletedInduction and Maintenance of General AnesthesiaChina
-
Haisco Pharmaceutical Group Co., Ltd.CompletedInduction and Maintenance of General AnesthesiaChina
-
Hospital Italiano de Buenos AiresUnknownTarget Controlled Infusion | Induction of Anesthesia | Bispectral IndexArgentina
-
Jakob ZeuchnerRecruitingComplication of Anesthesia | Compliant Behavior | Rapid Sequence Induction | RSISweden
-
Hospices Civils de LyonUnknownInduction of Total Intravenous General AnesthesiaFrance
-
Sohag UniversityRecruitingPain, During Injection of Propofol for Induction of AnesthesiaEgypt
Clinical Trials on HSK3486
-
Sichuan Haisco Pharmaceutical Group Co., LtdThe First Hospital of Jilin UniversityCompletedHealthy Elderly SubjectsChina
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompleted
-
Sichuan Haisco Pharmaceutical Group Co., LtdThe First Affiliated Hospital of Zhengzhou UniversityCompletedChronic Renal ImpairmentChina
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompletedAnesthesia | SedationChina
-
Sichuan Haisco Pharmaceutical Group Co., LtdWithdrawn
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompleted
-
Sichuan Haisco Pharmaceutical Group Co., LtdThe First Hospital of Jilin UniversityCompletedHepatic ImpairmentChina
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompletedInduction and Maintenance of General AnesthesiaChina
-
University of Medicine and Dentistry of New JerseyWithdrawn
-
OctapharmaTerminatedImmunologic Deficiency SyndromesAustria